<DOC>
	<DOCNO>NCT01465646</DOCNO>
	<brief_summary>The purpose study measure area curve ( AUC0-48h ; extent systemic availability ) maxi-mum concentration ( Cmax ) total serum levothyroxine ( TT4 , bind free fraction ) single pharmacological dose 600 μg administer tablet also contain iodine supple-ments vs. dose levothyroxine administer reference solution without iodine .</brief_summary>
	<brief_title>Bioavailability Investigations Thyronajod Mite Tablets Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine , 100 μg Levothyroxine/75 μg Iodine vs. Levothyroxine Drinking-Solution : A Randomised Cross Over Study Healthy Male Individuals . Currently : 100 μg/ 75 μg Tablets</brief_title>
	<detailed_description />
	<criteria>Euthyroid men Age : 18 50 Normal value fT4 und TSH Good state health Thyroid function disorder term subclinical overt hyper hypothyroidism History thyroid function disorder Focal diffuse autonomy thyroid gland Thyroid nodules &gt; 1 ml accord sonographic examination Any acute chronic illness Dermatitis herpetiformis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>levothyroxine</keyword>
	<keyword>bioavailability</keyword>
</DOC>